tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Holding IKT?
Track your performance easily

Inhibikase Therapeutics (IKT) Financial Statements

137 Followers

Inhibikase Therapeutics Financial Overview

Inhibikase Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.717; its P/E ratio is -0.74; Inhibikase Therapeutics is scheduled to report earnings on March 27, 2025, and the estimated EPS forecast is $-0.09. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Sep 23Jun 23Mar 23
Income Statement-
Total Revenue---$ 116.41K$ 64.52K
Gross Profit---$ 116.41K$ 64.52K
EBIT$ -5.05M$ -4.79M$ -4.77M$ -6.20M$ -4.71M
EBITDA$ -5.04M$ -4.78M$ -4.76M$ -6.04M$ -4.71M
Net Income Common Stockholders$ -4.96M$ -4.65M$ -4.60M$ -5.78M$ -4.48M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 7.94M$ 9.75M$ 16.83M$ 20.94M$ 25.72M
Total Assets$ 8.83M$ 11.07M$ 17.88M$ 22.35M$ 28.16M
Total Debt$ 177.83K$ 209.49K$ 270.04K$ 297.94K$ 325.01K
Net Debt$ -7.76M$ -9.54M$ -16.56M$ -20.64M$ -25.39M
Total Liabilities$ 3.73M$ 4.29M$ 2.86M$ 2.88M$ 2.84M
Stockholders Equity$ 5.10M$ 6.78M$ 15.02M$ 19.46M$ 25.32M
Cash Flow-
Free Cash Flow$ -5.05M$ -3.87M$ -4.11M$ -4.58M$ -5.97M
Operating Cash Flow$ -5.05M$ -3.87M$ -4.11M$ -4.57M$ -5.97M
Investing Cash Flow$ 2.54M$ -3.31M$ 17.06M$ 2.55M$ -5.84M
Financing Cash Flow$ 3.24M$ 367.00K$ 70.00$ -35.99K$ 8.58M
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History

Inhibikase Therapeutics Debt to Assets

Inhibikase Therapeutics Cash Flow

Inhibikase Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis